Kiniksa Pharmaceuticals Ltd. Statistics
Share Statistics
Kiniksa Pharmaceuticals Ltd. has 72.20M shares outstanding. The number of shares has increased by 102.18% in one year.
| Shares Outstanding | 72.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 68.98M |
| Failed to Deliver (FTD) Shares | 803 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 4.21M, so 5.84% of the outstanding shares have been sold short.
| Short Interest | 4.21M |
| Short % of Shares Out | 5.84% |
| Short % of Float | 6.11% |
| Short Ratio (days to cover) | 13.5 |
Valuation Ratios
The PE ratio is 87.25 and the forward PE ratio is 41.8. Kiniksa Pharmaceuticals Ltd.'s PEG ratio is 0.24.
| PE Ratio | 87.25 |
| Forward PE | 41.8 |
| PS Ratio | 4.55 |
| Forward PS | 2.6 |
| PB Ratio | 2.8 |
| P/FCF Ratio | 93.3 |
| PEG Ratio | 0.24 |
Enterprise Valuation
Kiniksa Pharmaceuticals Ltd. has an Enterprise Value (EV) of 1.13B.
| EV / Earnings | 80.46 |
| EV / Sales | 4.19 |
| EV / EBITDA | -49.58 |
| EV / EBIT | -44.97 |
| EV / FCF | 86.03 |
Financial Position
The company has a current ratio of 4.34, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.34 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.51 |
| Cash Flow / Debt | 5.9 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.03% and return on capital (ROIC) is 4.72%.
| Return on Equity (ROE) | 0.03% |
| Return on Assets (ROA) | 0.03% |
| Return on Capital (ROIC) | 4.72% |
| Revenue Per Employee | 909.96K |
| Profits Per Employee | 47.42K |
| Employee Count | 297 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.82 |
Taxes
| Income Tax | -30.74M |
| Effective Tax Rate | 1.85 |
Stock Price Statistics
The stock price has increased by 12.62% in the last 52 weeks. The beta is 0.35, so Kiniksa Pharmaceuticals Ltd.'s price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | 12.62% |
| 50-Day Moving Average | 23.38 |
| 200-Day Moving Average | 21.92 |
| Relative Strength Index (RSI) | 32.58 |
| Average Volume (20 Days) | 361.77K |
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals Ltd. had revenue of $270.26M and earned $14.08M in profits. Earnings per share was $0.2.
| Revenue | 270.26M |
| Gross Profit | 213.74M |
| Operating Income | -25.20M |
| Net Income | 14.08M |
| EBITDA | -22.86M |
| EBIT | -25.20M |
| Earnings Per Share (EPS) | 0.2 |
Balance Sheet
The company has $107.95M in cash and $12.26M in debt, giving a net cash position of $95.70M.
| Cash & Cash Equivalents | 107.95M |
| Total Debt | 12.26M |
| Net Cash | 95.70M |
| Retained Earnings | -477.95M |
| Total Assets | 555.30M |
| Working Capital | 215.35M |
Cash Flow
In the last 12 months, operating cash flow was $13.30M and capital expenditures -$130.00K, giving a free cash flow of $13.17M.
| Operating Cash Flow | 13.30M |
| Capital Expenditures | -130.00K |
| Free Cash Flow | 13.17M |
| FCF Per Share | 0.19 |
Margins
Gross margin is 79.09%, with operating and profit margins of -9.32% and 5.21%.
| Gross Margin | 79.09% |
| Operating Margin | -9.32% |
| Pretax Margin | -6.16% |
| Profit Margin | 5.21% |
| EBITDA Margin | -8.46% |
| EBIT Margin | -9.32% |
| FCF Margin | 4.87% |
Dividends & Yields
KNSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.99% |
| FCF Yield | 0.9% |
Analyst Forecast
The average price target for KNSA is $35, which is 72.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 72.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 7.08 |
| Piotroski F-Score | 3 |